Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of Gamma Knife Radiosurgery and Temozolomide (Temodar) for Newly Diagnosed Brain Metastases.

Next Previous
X
Search
Trial Profile

Phase II Study of Gamma Knife Radiosurgery and Temozolomide (Temodar) for Newly Diagnosed Brain Metastases.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Mar 2017

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Temozolomide (Primary)
  • Indications Brain cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 17 Sep 2015 As per NCT Primary end point was changed from "prevention of new brain metastases" to "Percentage of Participants With Distant Brain Failure (DBF) at One Year"
    • 17 Sep 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 25 Feb 2014 Planned End Date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrial.gov record..

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top